文献速递甲状腺疾病

Graves病患者启动抗甲状腺药物治疗25年后的结局

Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该研究对1997至2001年参与随机试验的Graves病患者进行回顾性随访,纳入原研究83%(182/218)的患者。随访结束时34%甲状腺功能正常,其余为活动性疾病(1%)、自发性甲状腺功能减退(13%)、放射性碘消融(40%)或甲状腺切除术(13%)。年龄≤40岁、甲状腺眼病、吸烟及白细胞介素6和TNFRS9升高增加复发风险。

要点

  • 随访25年后34%患者甲状腺功能正常,40%接受放射性碘治疗,13%行甲状腺切除术。
  • 年龄≤40岁、甲状腺眼病、吸烟、IL-6和TNFRS9升高与复发风险增加相关。
  • 47%患者合并至少一种自身免疫病,包括维生素B12缺乏(26%)和类风湿关节炎(5%)。

核心结论

  • 需要终身仔细监测以发现复发、甲状腺功能减退和其他自身免疫病。
  • 长期抗甲状腺药物治疗可作为有益的一线治疗选择,尤其适用于发病年龄小或存在甲状腺眼病的患者。

研究设计与样本

  • 回顾性随访研究,纳入1997至2001年参与随机试验的Graves病患者,共182例(占原研究83%,182/218)。
  • 从医疗记录和问卷获取人口学和临床数据,分析生物样本库样本中的炎症生物标志物并与年龄性别匹配的健康个体比较。

主要发现

  • 随访结束时34%患者甲状腺功能正常,1%为活动性疾病,13%为自发性甲状腺功能减退,40%接受放射性碘消融治疗,13%接受甲状腺切除术。
  • 年龄≤40岁、甲状腺眼病、吸烟、白细胞介素6升高和TNFRS9升高增加复发风险,比值比分别为3.22、2.26、2.21、1.99、2.36。
  • 治疗结束时,维持甲状腺功能正常者的CD40较低(P = .04)。
  • 随访结束时47%患者有一种或以上自身免疫病,包括维生素B12缺乏(26%)和类风湿关节炎(5%)。
  • 发生甲状腺功能减退的Graves病患者生活质量下降。

关键数值与推荐

  • 年龄≤40岁、甲状腺眼病、吸烟、白细胞介素6升高、TNFRS9升高与复发风险增加相关,比值比分别为3.22、2.26、2.21、1.99、2.36。
  • 治疗结束时维持甲状腺功能正常者CD40较低(P = .04)。

临床怎么用

  • 原文结论指出需要终身仔细监测以发现复发、甲状腺功能减退和其他自身免疫病。
  • 长期抗甲状腺药物治疗可作为有益的一线治疗选择,尤其适用于发病年龄小或存在甲状腺眼病的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Graves disease (GD) is a leading cause of hyperthyroidism. Detailed investigations and predictors of long-term outcomes are missing. OBJECTIVE: This work aimed to investigate the outcomes in GD 25 years after initiating antithyroid drug treatment, including disease course, clinical and biochemical predictors of relapse, and quality of life. METHODS: A retrospective follow-up was conducted of GD patients that participated in a randomized trial from 1997 to 2001. Demographic and clinical data were obtained from medical records and questionnaires. Biobank samples were analyzed for inflammatory biomarkers and compared with age- and sex-matched healthy individuals. RESULTS: We included 83% (182/218) of the patients from the original study. At the end of follow-up, normal thyroid function was achieved in 34%. The remaining had either active disease (1%), spontaneous hypothyroidism (13%), or had undergone ablative treatment with radioiodine (40%) or thyroidectomy (13%). Age younger than or equal to 40 years, thyroid eye disease (TED), smoking, and elevated levels of interleukin 6 and tumor necrosis factor receptor superfamily member 9 (TNFRS9) increased the risk of relapsing disease (odds ratio 3.22; 2.26; 2.21; 1.99; 2.36). At the end of treatment, CD40 was lower in patients who maintained normal thyroid function (P = .04). At the end of follow-up, 47% had one or more autoimmune diseases, including vitamin B12 deficiency (26%) and rheumatoid arthritis (5%). GD patients who developed hypothyroidism had reduced quality of life. CONCLUSION: Careful lifelong monitoring is indicated to detect recurrence, hypothyroidism, and other autoimmune diseases. Long-term ATD treatment emerges as a beneficial first-line treatment option, especially in patients with young age at onset or presence of TED.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Meling Stokland AE, Austdal M, Nedrebø BG, et al. Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy. J Clin Endocrinol Metab. 2024. PMID: 37747433. doi:10.1210/clinem/dgad538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。